FDA Rejects Moderna's mRNA Flu Vaccine Over Trial Design

Establishment-critical narrative

Requiring rigorous trials with proper controls strengthens vaccine trust and regulatory integrity. The FDA should demand higher standards for approval, especially for drugs treating common conditions, and Prasad is making sure those standards are met. Forcing industry to fund more robust studies improves the entire system.